Niclosamide
Niclocide (niclosamide) is a small molecule pharmaceutical. Niclosamide was first approved as Niclocide on 1982-05-14. It is used to treat helminthiasis in the USA. It is known to target potassium channel subfamily T member 1 and neuropeptide Y receptor type 4-2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| helminthiasis | EFO_1001342 | D006373 | B65-B83 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | 4 | 10 | 3 | 1 | — | 16 |
| Treatment outcome | D016896 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | 3 | 1 | — | — | 3 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | — | 1 | — | — | 1 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 2 | 1 | — | — | — | 3 |
| Carcinoma | D002277 | — | C80.0 | 2 | 1 | — | — | — | 3 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | — | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Adenomatous polyposis coli | D011125 | — | D13.91 | — | 1 | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 1 | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | 1 | — | — | — | 1 |
| Proctitis | D011349 | EFO_0005628 | K62.89 | 1 | 1 | — | — | — | 1 |
| Proctocolitis | D011350 | EFO_1001223 | — | 1 | 1 | — | — | — | 1 |
| Ulcer | D014456 | MPATH_579 | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Taeniasis | D013622 | EFO_1001433 | B68 | — | — | — | — | 1 | 1 |
| Parasitic intestinal diseases | D007411 | EFO_0009561 | B82 | — | — | — | — | 1 | 1 |
| Urinary incontinence | D014549 | — | R32 | — | — | — | — | 1 | 1 |
| Stress urinary incontinence | D014550 | — | — | — | — | — | — | 1 | 1 |
| Enuresis | D004775 | — | R32 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Niclosamide |
| INN | niclosamide |
| Description | Niclosamide is a secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections. It has a role as a piscicide, a molluscicide, an antiparasitic agent, an anticoronaviral agent, an anthelminthic drug, an apoptosis inducer and a STAT3 inhibitor. It is a member of monochlorobenzenes, a member of salicylanilides, a C-nitro compound, a secondary carboxamide and a member of benzamides. It is functionally related to a 5-chlorosalicylic acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 50-65-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1448 |
| ChEBI ID | — |
| PubChem CID | 4477 |
| DrugBank | DB06803 |
| UNII ID | 8KK8CQ2K8G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNT1
KCNT1
Organism
Homo sapiens
Gene name
KCNT1
Gene synonyms
KIAA1422
NCBI Gene ID
Protein name
potassium channel subfamily T member 1
Protein synonyms
KCa4.1, potassium channel, sodium activated subfamily T, member 1, potassium channel, subfamily T, member 1, Sequence like a calcium-activated K+ channel
Uniprot ID
Mouse ortholog
Kcnt1 (227632)
potassium channel subfamily T member 1 (Q8C3E7)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,569 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use